{"pmid":32265035,"title":"[French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak].","text":["[French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak].","Bull Cancer","Penel, Nicolas","Bonvalot, Sylvie","Minard, Veronique","Orbach, Daniel","Gouin, Francois","Corradini, Nadege","Brahmi, Mehdi","Marec-Berard, Perrine","Briand, Sylvain","Gaspar, Nathalie","Llacer, Carmen","Carrere, Sebastien","Dufresne, Armelle","Le Cesne, Axel","Blay, Jean-Yves","32265035"],"journal":"Bull Cancer","authors":["Penel, Nicolas","Bonvalot, Sylvie","Minard, Veronique","Orbach, Daniel","Gouin, Francois","Corradini, Nadege","Brahmi, Mehdi","Marec-Berard, Perrine","Briand, Sylvain","Gaspar, Nathalie","Llacer, Carmen","Carrere, Sebastien","Dufresne, Armelle","Le Cesne, Axel","Blay, Jean-Yves"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265035","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.bulcan.2020.03.009","keywords":["COVID-19","Management","Prise en charge","Sarcoma","Sarcome"],"source":"PubMed","weight":0,"_version_":1663609715765018625,"score":7.9164424,"similar":[{"pmid":32278878,"title":"French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak.","text":["French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak.","Ann Oncol","Penel, N","Bonvalot, S","Minard, V","Orbach, D","Gouin, F","Corradini, N","Brahmi, M","Marec-Berard, P","Briand, S","Gaspar, N","Llacer, C","Carrere, S","Dufresne, A","Le Cesne, A","Blay, J Y","32278878"],"journal":"Ann Oncol","authors":["Penel, N","Bonvalot, S","Minard, V","Orbach, D","Gouin, F","Corradini, N","Brahmi, M","Marec-Berard, P","Briand, S","Gaspar, N","Llacer, C","Carrere, S","Dufresne, A","Le Cesne, A","Blay, J Y"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278878","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.annonc.2020.03.308","keywords":["COVID-19","management","sarcoma"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1663890921988554752,"score":222.40823},{"pmid":32222433,"pmcid":"PMC7103920","title":"[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","text":["[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus.","Gynecol Obstet Fertil Senol","Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C","32222433"],"abstract":["INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus."],"journal":"Gynecol Obstet Fertil Senol","authors":["Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222433","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.gofs.2020.03.017","keywords":["COVID-19","Cancer gynecologique","Guideline","Gynaecological cancer","Management","Prise en charge","Recommandation"],"source":"PubMed","locations":["ovarian"],"topics":["Treatment"],"weight":1,"_version_":1663352135224393728,"score":133.58508},{"pmid":32247066,"pmcid":"PMC7118621","title":"Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","text":["Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance.","J Gynecol Obstet Hum Reprod","Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril","32247066"],"abstract":["INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance."],"journal":"J Gynecol Obstet Hum Reprod","authors":["Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247066","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jogoh.2020.101729","keywords":["COVID-19","Guideline","Gynaecological cancer","Management"],"source":"PubMed","locations":["ovarian"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1663352136154480640,"score":77.025986},{"pmid":32277387,"title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-nCoV","COVID-19","Liver transplantation","Management"],"source":"PubMed","locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1663798882904047616,"score":57.46321},{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1663352134282772480,"score":55.487732}]}